Tracer library / [18F]MK-6240
[18F]MK-6240
Also written as [18F]MK-6240; [18F]MK6240; [F-18]MK-6240; [F-18]MK6240; F-18 MK-6240; F-18 MK6240; F-18-MK6240
- Radionuclide
- F-18 t½ 109.7 min
- Modality
- PET
- Production route
- Cyclotron liquid target
- Stage
- Approved
- Syntheses indexed
- 2
What it is
Regulatory status
- FDA
- Yes — 2026; TAUKLARIFY (florquinitau F 18); Cerveau Technologies / Lantheus; NDA 220496 Drugs@FDA, NDA 220496, approved 2026-08-13 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process&searchTerm=florquinitau
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- Tauklarify (US, FDA)
Clinical use
- Typical injected activity
- —
- Uptake time
- Brain PET acquired ~90-110 min after injection (dynamic and dual-time-window protocols also used) PMID 41591778 / DOI 10.1001/jamanetworkopen.2025.54524
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Synthera+ IBA | — | HPLC | 9.8% ± 1.8% decay-corrected | — | N-[(tert-butoxy)carbonyl]-N-(6-nitro-3-[1H-p…N-[(tert-butoxy)carbonyl]-N-(6-nitro-3-[1H-pyrrolo[2,3-c]pyridin-1-yl]isoquinolin-5-yl) carbamate | 30426529 2019 J Labelled Comp Radiopharm The synthesis was performed automatically with a single-use cassette on an IBA Synthera+ synthesis module. - resulting in an isolated radiochemical yield of 9.8% ± 1.8% (n = 3) calculated from the end of bombardment (5.2% ± 1.0% calculated from the end of synthesis). |
| TRACERlab FX FN GE HealthCare | — | HPLC | 7.5% ± 1.9% not corrected | — | 5-diBoc-6-nitro precursor | 28185305 2017 J Labelled Comp Radiopharm a commercially available radiosynthesis module, GE Healthcare TRACERlab FXFN - in an uncorrected radiochemical yield of 7.5% ± 1.9% (relative to starting [18 F]fluoride) |
Clinical literature
Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.
- Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform.2024 · EBioMedicine · Clinical study
Precursor
- Common precursor
- Bis-Boc-protected 6-nitro precursor; nucleophilic [18F]fluorination (SNAr displacing the nitro group) then acid deprotection and HPLC PMID 28185305
- Suppliers seen in the literature
- —
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [18F]MK-6240, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]MK-6240.
Get in touchNotes
Added at user request.